The Japanese Society of Hypertension (JSH) revised the Guidelines for the Management of
Hypertension 2014 (JSH 2014), and published the JSH 2019. In the development of the JSH …

Executive summary Elevated blood pressure is the strongest modifiable risk factor for
cardiovascular disease worldwide. Despite extensive knowledge about ways to prevent as …

Every 5 years, the JAS publishes guidelines for the treatment of dyslipidemia and
atherosclerosis. To date, this society has released four such guidelines. Since 2007, the JAS …

Background The presence and implications of abnormal arterial stiffness, a potential
independent predictor of outcomes, in community‐dwelling treated hypertensives is …

Background The effect of very high or extremely high levels of high-density lipoprotein
cholesterol (HDL-C) on cardiovascular disease (CVD) is not well described. Although a few …

Aim: To investigate the relationship between serum uric acid levels and cardiovascular
disease in Asians. Methods: We examined the above relationship using the data of …

BACKGROUND: Home blood pressure (BP) is an important component of digital strategies
for hypertension management. However, no studies have used the same device to …

The SPRINT (Systolic Blood Pressure Intervention Trial) reported that some older, higher
risk patients might benefit from a target systolic blood pressure (BP) of< 120 versus< 140 …

Hypertension has been reported as a major risk factor for diseases such as cardiovascular
disease, and associations between platelet activation and risk for hypertension are well …

Background Hypertensive individuals on blood pressure (BP)–lowering treatment with BP in
the normal or high‐normal range have higher cardiovascular risk than untreated persons …